Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
von Birgelen C, Sen H, Lam MK, Danse PW, Jessurun GA, Hautvast RW, van Houwelingen GK, Schramm AR, Gin RM, Louwerenburg JW, de Man FH, Stoel MG, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, Basalus MW, Doggen CJ, Tandjung K. von Birgelen C, et al. Among authors: lam mk. Lancet. 2014 Feb 1;383(9915):413-23. doi: 10.1016/S0140-6736(13)62037-1. Epub 2013 Oct 31. Lancet. 2014. PMID: 24183564 Clinical Trial.
Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
Tandjung K, Sen H, Lam MK, Basalus MWZ, Louwerenburg JHW, Stoel MG, van Houwelingen KG, de Man FHAF, Linssen GCM, Saïd SAM, Nienhuis MB, Löwik MM, Verhorst PMJ, van der Palen J, von Birgelen C. Tandjung K, et al. Among authors: lam mk. J Am Coll Cardiol. 2013 Jun 18;61(24):2406-2416. doi: 10.1016/j.jacc.2013.04.005. Epub 2013 Apr 16. J Am Coll Cardiol. 2013. PMID: 23602769 Free article. Clinical Trial.
Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Sen H, Lam MK, Tandjung K, Löwik MM, Stoel MG, de Man FH, Louwerenburg JH, van Houwelingen GK, Linssen GC, Doggen CJ, Basalus MW, von Birgelen C. Sen H, et al. Among authors: lam mk. Catheter Cardiovasc Interv. 2015 Jan 1;85(1):74-81. doi: 10.1002/ccd.25464. Epub 2014 Mar 14. Catheter Cardiovasc Interv. 2015. PMID: 24585502 Clinical Trial.
Coronary artery dominance and the risk of adverse clinical events following percutaneous coronary intervention: insights from the prospective, randomised TWENTE trial.
Lam MK, Tandjung K, Sen H, Basalus MW, van Houwelingen KG, Stoel MG, Louwerenburg JW, Linssen GC, Saïd SA, Nienhuis MB, de Man FH, van der Palen J, von Birgelen C. Lam MK, et al. EuroIntervention. 2015 Jun;11(2):180-7. doi: 10.4244/EIJV11I2A32. EuroIntervention. 2015. PMID: 24602919 Free article. Clinical Trial.
Comparison of 3 biodegradable polymer and durable polymer-based drug-eluting stents in all-comers (BIO-RESORT): rationale and study design of the randomized TWENTE III multicenter trial.
Lam MK, Sen H, Tandjung K, van Houwelingen KG, de Vries AG, Danse PW, Schotborgh CE, Scholte M, Löwik MM, Linssen GC, Ijzerman MJ, van der Palen J, Doggen CJ, von Birgelen C. Lam MK, et al. Am Heart J. 2014 Apr;167(4):445-51. doi: 10.1016/j.ahj.2013.11.014. Epub 2014 Jan 6. Am Heart J. 2014. PMID: 24655691 Free article. Review.
Clinical outcome of patients with implantation of second-generation drug-eluting stents in the right coronary ostium: insights from 2-year follow-up of the TWENTE trial.
Lam MK, Sen H, Tandjung K, Löwik MM, Basalus MW, Mewes JC, Stoel MG, van Houwelingen KG, Linssen GC, Ijzerman MJ, Doggen CJ, von Birgelen C. Lam MK, et al. Catheter Cardiovasc Interv. 2015 Mar;85(4):524-31. doi: 10.1002/ccd.25518. Epub 2014 May 8. Catheter Cardiovasc Interv. 2015. PMID: 24753036 Clinical Trial.
Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and non-enrolled TWENTE registry.
Sen H, Lam MK, Tandjung K, Löwik MM, van Houwelingen KG, Stoel MG, Louwerenburg HW, de Man FH, Linssen GC, Grandjean JG, Doggen CJ, von Birgelen C. Sen H, et al. Among authors: lam mk. Int J Cardiol. 2014 Oct 20;176(3):885-90. doi: 10.1016/j.ijcard.2014.08.036. Epub 2014 Aug 13. Int J Cardiol. 2014. PMID: 25168098 Free article. Clinical Trial.
Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial.
Sen H, Lam MK, Tandjung K, Basalus MW, de Man FH, Louwerenburg JH, Stoel MG, van Houwelingen GK, Löwik MM, Linssen GC, Saïd SA, Nienhuis MB, Verhorst PM, van der Palen J, von Birgelen C. Sen H, et al. Among authors: lam mk. EuroIntervention. 2014 Oct;10(6):664-71. doi: 10.4244/EIJV10I6A117. EuroIntervention. 2014. PMID: 25330500 Free article. Clinical Trial.
Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial.
van Houwelingen KG, Sen H, Lam MK, Tandjung K, Löwik MM, de Man FH, Louwerenburg JH, Stoel MG, Hartmann M, Linssen GC, Doggen CJ, von Birgelen C. van Houwelingen KG, et al. Among authors: lam mk. Catheter Cardiovasc Interv. 2015 Feb 15;85(3):E76-82. doi: 10.1002/ccd.25713. Epub 2014 Nov 1. Catheter Cardiovasc Interv. 2015. PMID: 25339110 Clinical Trial.
152 results